Home›Mao Inhibitors›Mao Inhibitors + Meloxicam

Does Mao Inhibitors Interact with Meloxicam?

CDI records a major classification for Mao Inhibitors and Meloxicam. The stored summary is: NSAIDs may diminish antihypertensive effects and result in renal function deterioration or acute renal failure in elderly, volume-depleted, or renally impaired patients. The mechanism involves nsaid-mediated reduction in renal perfusion and antihypertensive effect inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Major
Meloxicam Class
Nonsteroidal Anti-inflammatory Drug
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

NSAID-mediated reduction in renal perfusion and antihypertensive effect inhibition

What To Tell Your Doctor or Pharmacist

If you are taking Mao Inhibitors and your doctor is considering prescribing Meloxicam (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Mao Inhibitors+💊 Meloxicam(Metacam)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
Nonsteroidal Anti-inflammatory Drug
Source
NLP:meloxicam

What this means in plain English

NSAIDs may diminish antihypertensive effects and result in renal function deterioration or acute renal failure in elderly, volume-depleted, or renally impaired patients.

About Mao Inhibitors and Meloxicam

Meloxicam is a Nonsteroidal Anti-inflammatory Drug. Meloxicam is also sold under the brand name Metacam. Meloxicam additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:meloxicam

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Mao Inhibitors and Meloxicam against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations